Curcumin and neurodegenerative diseases: A perspective

Expert Opinion on Investigational Drugs

Volumn 21, Issue 8, 2012, Pages 1123-1140

  Darvesh, Altaf S ^a,b   Carroll, Richard T ^a   Bishayee, Anupam ^c   Novotny, Nicholas A ^a   Geldenhuys, Werner J ^a   Van Der Schyf, Cornelis J ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeast Ohio Medical University   (United States)

^c American University of Health Sciences   (United States)

Author keywords

Alzheimer; curcumin; inflammation; oxidative stress; Parkinson; polyphenols; protein aggregation; s disease

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASCORBIC ACID; BETA CATENIN; CATALASE; CURCUMA LONGA EXTRACT; CURCUMIN; CYCLOOXYGENASE 2; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; EPIGALLOCATECHIN GALLATE; GLUTATHIONE PEROXIDASE; I KAPPA B KINASE BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RESVERATROL; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOIMMUNE DISEASE; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CELL DEATH; CLINICAL TRIAL (TOPIC); CURCUMA LONGA; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENDOCRINE DISEASE; HUMAN; HYPERKERATOSIS; HYPERPLASIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID PEROXIDATION; NEOPLASM; NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; REVIEW; ULCER;

ANIMALS; CURCUMIN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 84863641930     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.693479     Document Type: Review

References (165)

1. Duthie GG, Gardner PT, Kyle JA. Plant polyphenols: are they the new magic bullet? Proc Nutr Soc 2003;62:599-603 (Pubitemid 37152845)
2. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2009;2:270-8
3. Obrenovich ME, Nair NG, Beyaz A, et al. The role of polyphenolic antioxidants in health, disease, and aging. Rejuvenation Res 2010;13:631-43
4. Queen BL, Tollefsbol TO. Polyphenols and aging. Curr Aging Sci 2010;3:34-42
5. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 2004;37:304-17 (Pubitemid 38833997)
6. Aggarwal BB, Shishodia S. Resveratrol in health and disease. CRC Press Taylor & Francis Group; Boca Raton, Fl: 2006
7. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009;30:85-94
8. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009;2:409-18
9. Seeram NP. Emerging research supporting the positive effects of berries on human health and disease prevention. J Agric Food Chem 2012; In press
10. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40-9 Excellent overview of the therapeutic potential of curcumin.
11. Sethi G, Sung B, Aggarwal BB. The role of curcumin in modern medicine. herbal drugs: ethnomedicine to modern medicine. Springer-Verlag; Berlin, Heidelberg; 2009. p. 97-113
12. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol 2012;13:218-28
13. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011;12:332-47
14. Balasubramanian K. Molecular orbital basis for yellow curry spice curcumin's prevention of Alzheimer's disease. J Agric Food Chem 2006;54:3512-20 (Pubitemid 43844175)
15. Esptein J, Sanderson IR, MacDonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 2010;103:1545-57
16. Cole GM, Yang F, Lim GP, et al. A rationale for curcuminoids for the prevention or treatment of Alzheimer's disease. Curr Med Chem-Immun Endoc Metab Agents 2003;3:15-25 A review of the therapeutic potential of curcuminoids in Alzheimer's disease.
17. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 2008;11:13-19 (Pubitemid 351550812)
18. Sun AY, Wang Q, Simonyi A, et al. Botanical phenolics and brain health. Neuromolecular Med 2008;10:259-74
19. Darvesh AS, Carroll RT, Bishayee A, et al. Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev Neurother 2010;10:729-45 A systematic review of the therapeutic potential of polyphenolic compounds of dietary origin in Alzheimer's disease.
20. Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 2010;112:1415-30
21. Scapagnini G, Caruso C, Calabrese V. Therapeutic potential of dietary polyphenols against brain aging and neurodegenerative disorders. bio-farms for nutraceuticals: functional food and safety control by biosensors. Landes Bioscience and Springer Science+Business Media; Berlin, Heidelberg: 2010. p. 27-35
22. Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs 2011;20:13-22
23. Kulkarni SK, Dhir A. An overview of curcumin in neurological disorders. Indian J Pharm Sci 2010;72:149-54
24. Bishnoi M, Chopra K, Kulkarni SK. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioral, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav 2008;88:511-22 (Pubitemid 350266795)
25. Xu Y, Ku BS, Yao HY, et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005;518:40-46 (Pubitemid 40968146)
26. Kulkarni SK, Akula KK, Deshpande J. Evaluation of antidepressant-like activity of novel water-soluble curcumin formulations and St. john's Wort in behavioral paradigms of despair. Pharmacology 2012;89:83-90
27. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's Dement 2009;5:234-70
28. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010;15:7792-814
29. Amor S, Puentes F, Baker D, et al. Inflammation in neurodegenerative diseases. Immunology 2011;129:154-69
30. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 2011;8:26
31. Rossi L, Mazzitelli S, Arciello M, et al. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res 2008;33:2390-400
32. Calabrese V, Cornelius C, Mancuso C, et al. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front Biosci 2009;14:376-97 An in-depth review of the cytoprotective properties of dietary antioxidants in modulating the stress response in neurodegeneration.
33. Zhao B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem Res 2009;34:630-8
34. Ravindran PN. Turmeric-the golden spice of life. turmeric: the genus Curcuma. Taylor and Francis Group; London; 2006. p. 1-14 An excellent resource for turmeric.
35. Aggarwal BB, Sundaram C, Malani N, et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75 An in-depth and well-written review on curcumin.
36. Aggarwal BB, Bhatt ID, Ichikawa H, et al. Curcumin-biological and medicinal properties. turmeric: the genus Curcuma. Taylor and Francis Group; London; 2006. p. 297-368
37. Sarkar FH, Li Y, Wang Z, Padhye S. Lessons learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des 2010;16:1801-12
38. Geldenhuys WJ, Bishayee A, Darvesh AS, et al. Natural products of dietary origin as lead compounds in virtual screening and drug design. Curr Pharm Biotechnol 2012;13:117-24
39. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18 A review of the bioavailability aspects of curcumin.
40. Suresh D, Srinivasan K. Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. Indian J Med Res 2010;131:682-91
41. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008;326:196-208 (Pubitemid 351872144)
42. Mythri RB, Bharath MS. Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr Pharm Des 2012;18:91-9
43. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-6 (Pubitemid 28234275)
44. Shaikh J, Ankola DD, Beniwal V, et al. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009;37:395-404
45. Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanoparticles with very high affinity for amyloid-beta1-42 peptide. Biomaterials 2011;32:1635-45
46. Taylor M, Moore S, Mourtas S, et al. Effect of curcumin-associated and lipid ligand functionalised nanoliposomes on aggregation of the Alzheimer's Abeta peptide. Nanomedicine 2011;7:541-50
47. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PGLA nanoparticles conjugated with tet-1 peptide for potential use in Alzheimer's disease. PLoS ONE 2012;7:e32616
48. Kumar A, Ahuja A, Ali J, et al. Conundrum and therapeutic potential of curcumin in drug delivery. Crit Rev Ther Drug Carrier Syst 2010;27:279-312 An excellent commentary on the development of drug delivery for curcumin.
49. Gota VS, Maru GB, Soni TG, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 2010;58:2095-9
50. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 2012;17:71-80
51. John VD, Kuttan G, Krishnakutty K. Anti-tumor studies of metal chelates of synthetic curcuminoids. J Exp Clin Cancer Res 2002;21:219-24 (Pubitemid 34785558)
52. De Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr 2008;47:51-9 (Pubitemid 351644180)
53. Yang CS, Sang S, Lambert JD, et al. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 2008;52:139-51
54. Scheepens A, Tan K, Paxton JW. Improving the oral bioavailability of beneficial polyphenols through designed synergies. Genes Nutr 2010;5:75-87
55. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethyoxycurcumin, bisdemethoxyxurcumin, tetrahydrocurcumin, and tumerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis 2007;8:1765-73 (Pubitemid 47289040)
56. Khafif A, Schantz SP, Chou TC, et al. Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 1998;19:419-24 (Pubitemid 28375443)
57. Sharma M, Mahoharlal R, Negi AS, et al. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Res 2010;10:570-8
58. Jovanovic SV, Boone CW, Steenken S, et al. How curcumin works preferentially with water soluble antioxidants. J Am Chem Soc 2001;123:3064-8 (Pubitemid 32879574)
59. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75:787-809
60. Burgos-Morón E, Calderón-Montano JM, Salvador J, et al. The dark side of curcumin. Int J Cancer 2010;126:1771-5 A critique of the toxic potential of curcumin.
61. National Toxicology Program Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-1) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program 1993;427:1-275
62. Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130:467S-71S (Pubitemid 30073775)
63. Strong R, Miller RA, Astle CM, et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2012; doi: 10.1093/gerona/gls070 PMID: 22451473. [Epub ahead of print]
64. Mancuso C, Barone E. Curcumin in clinical practice: myth or reality? Trends Pharmacol Sci 2009;30:333-4
65. Mancuso C, Siciliano R, Barone E. Curcumin and Alzheimer's disease: this marriage is not to be performed. J Biol Chem 2011;286:le3
66. Bishayee A, Darvesh AS. Oxidative stress in cancer and neurodegerative diseases: prevention and treatment by dietary antioxidants. handbook of free radicals: formation, types and effects. Nova Science Publishers; Hauppauge, New York; 2010. p. 1-67
67. Jayaprakasha GK, Rao LJ, Sakariah KK. Antioxidant activities of curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food Chem 2006;98:720-4
68. Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008;174:27-37
69. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the beta-diketone moiety in the antioxidant mechanism of tetrahydrocurcumin. Biochem Pharmacol 1996;52:519-25 (Pubitemid 26253384)
70. Motterlini R, Foresti R, Bassi R, et al. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000;28:1303-12 (Pubitemid 30417475)
71. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005;16:263-75 (Pubitemid 40283941)
72. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21 (Pubitemid 44666739)
73. Pan MH, Lai CS, Ho CT. Anti-inflammatory activity of natural dietary flavonoids. Food Funct 2010;1:15-31
74. Gonzalez R, Ballester I, Lopez-Posadas R. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr 2011;51:331-62
75. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-215
76. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011;16:4567-98
77. Recio MC, Andujar I, Rios JL. Anti-inflammatory agents from plants: progress and potential. Curr Med Chem 2012; In press
78. Gupta SC, Kim JH, Prasad H, et al. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis, of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010;29:405-34
79. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008;233:21-31
80. Singh S, Aggarwal BB. Activation of transcription factor NF-kappaB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995;270:24995-5000 Description of the anti-inflammatory properties of curcumin.
81. Sikora-Polaczek M, Bielak-Zmijewska A, Sikora E. Molecular and cellular mechanisms of curcumin action - beneficial effect on organism. Postepy Biochem 2011;57:74-84
82. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol 2007;595:127-48
83. Rahman I, Marwick J, Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol 2004;68:1255-67 (Pubitemid 39094292)
84. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007;595:197-212 An excellent summary of the neuroprotective properties of curcumin.
85. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:1634-58 (Pubitemid 43873658)
86. Kopec KK, Carroll RT. Phagocytosis is regulated by nitric oxide in murine microglia. Nitric Oxide 2000;4:103-11 (Pubitemid 30318300)
87. Butterfield DA, Reed T, Newman SF, et al. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007;43:658-77 (Pubitemid 47102132)
88. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006;29:518-27 (Pubitemid 44291819)
89. Gupta SC, Patchva S, Koh W, et al. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39:283-99
90. Esposito E, Cuzzocrea S. New therapeutic strategy for Parkinson's and Alzheimer's disease. Curr Med Chem 2010;17:2764-74
91. Song JX, Sze SC, Ng TB, et al. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 2012;139:698-711 A review of the pharmacological effects of natural products in pre-clinical models of Parkinson's disease.
92. Craggs L, Kalaria RN. Revisiting dietary antioxidants, neurodegenration and dementia. Neuroreport 2011;22:1-3
93. Mancuso C, Siciliano R, Barone E, et al. Natural substances and Alzhemier's disease: from preclinical studies to evidence based medicine. Biochim Biophys Acta 2012;1822:616-24 A review of the clinical development of curcumin.
94. Ganguli M, Chandra V, Kamboh M, et al. Apolipoprotein E polymorphism and Alzheimer's disease: the Indo-US Cross-National Dementia Study. Arch Neurol 2000;57:824-30 (Pubitemid 30397184)
95. Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer's disease in a rural community in India, the Indo-US study. Neurology 2001;57:985-9 (Pubitemid 32880190)
96. Ng TP, Chiam PC, Lee T, et al. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006;164:898-906 (Pubitemid 44627275)
97. Van Marum RJ. Current and future therapy of Alzheimer's disease. Fundam Clin Pharmacol 2008; 22:265-74 (Pubitemid 351712889)
98. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 2008;29:609-15
99. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008;14:45-53
100. Ray B, Lahiri DK. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009;9:434-44
101. Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010;16:285-97
102. Ringman JM, Frautschy SA, Cole GM, et al. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005;2:131-6 (Pubitemid 40862872)
103. Frautschy SA, Cole GM. Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 2010;41:392-409 An excellent perspective on the need for developing novel therapeutic strategies for Alzheimer's disease.
104. Kuner PK, Schbenel R, Hertel C. beta-Amyloid binds to p75NTR and activates NFkB in human neuroblastoma cells. J Neurosci Res 1998;54:798-804 (Pubitemid 28544380)
105. Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA (1-42) insult. Neurosci Lett 2001;303:57-61 (Pubitemid 32285467)
106. Ono K, Hasegawa K, Naiki H, et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004;75:742-50 (Pubitemid 38296087)
107. Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem 2004;91:1199-210 (Pubitemid 39587458)
108. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-01
109. Park SY, Kim HS, Cho EK, et al. Curcumin protected PC12 cells against beta-amyloid-induced toxicity and inhibition of oxidative damage and tau hyperphosphorylation. Food Chem Toxicol 2008;46:2881-7
110. Shytle RD, Bickford PC, Rezai-zadeh K, et al. Optimized turmeric extracts have potent anti-amyloidogenic effects. Curr Alzheimer Res 2009;6:564-71
111. Guo JP, Yu S, McGeer PL. Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J Alzheimer's Dis 2010;19:1357-70
112. Varghese K, Molnar P, Das M, et al. A new target for amyloid beta toxicity validated by standard and high-throughput electrophysiology. PLoS ONE 2010;5:8643
113. Zhang C, Browne A, Child D, et al. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 2010;285:28472-80
114. Mulik RS, Monkkonen J, Juvonen RO, et al. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm 2010;7:815-25
115. Qin XY, Cheng Y, Yu LC. Potential protection of curcumin against intracellular amyloid beta-induced toxicity in cultured rat prefrontal cortical neurons. Neurosci Lett 2010;480:21-4
116. Liu H, Li Z, Qui D. The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 2010;485:83-8
117. Ahmed T, Gilani AH, Hosseinmardi N, et al. Curcuminoids rescue long-term potentiation impaired by amyloid peptide in rat hippocampal slices. Synapse 2011;65:572-82
118. Mishra S, Mishra M, Seth P. Tetrahydrocurcumin confers protection against amyloid beta-induced toxicity. Neuroreport 2011;22:23-7
119. Li YY, Cui JG, Hill JM, et al. Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models. Neurosci Lett 2011;487:94-8
120. Xiong Z, Hongmei Z, Lu S, et al. Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer's disease. Pharmacol Rep 2011;63:1101-8
121. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001;22:993-1005 A pioneering study that highlighted the neuroprotective effects of curcumin in an animal model of Alzheimer's disease. (Pubitemid 34070638)
122. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-7 (Pubitemid 33051435)
123. Garcia-Alloza M, Borelli LA, Rozkalne A, et al. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neuritis in an Alzheimer mouse model. J Neurochem 2007;102:1095-104 (Pubitemid 47174225)
124. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008;326:196-208 (Pubitemid 351872144)
125. Pan R, Qiu S, Lu DX, Dong J. Curcumin improves learning and memory ability and its neuroprotective mechanism. Chin Med J (Engl) 2008;121:832-9
126. Wang YJ, Thomas P, Zhong JH, et al. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 2009;15:3-14
127. Hamaguchi T, Ono K, Murase A, et al. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 2009;175:2557-65
128. Ahmed T, Enam SA, Gilani AH. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 2010;169:1296-306
129. Kulkarni AP, Govender DA, Kotwal GJ, et al. Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease. Curr Alzheimer Res 2011;8:95-113
130. Kumar A, Prakash A, Dogra S. Protective effect of curcumin (Curcuma longa) against D-galactose-induced senescence in mice. J Asian Nat Prod Res 2011;13:42-55
131. Kakkar V, Kaur IP. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioral, biochemical and histopathological alteration in mice brain. Food Chem Toxicol 2011;49:2906-13
132. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1983-93
133. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76 (Pubitemid 351441488)
134. Mehlhornand RJ, Cole GM. The free radical theory of aging: a critical review. Adv Radical Biol Med 1985;1:165-223
135. Napolitano A, Manini P, d'Ischia M. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem 2011;18:1832-45
136. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510-18
137. Hong JS. Role of inflammation in the pathogenesis of Parkinson's disease: models, mechanisms, and therapeutic interventions. Ann NY Acad Sci 2005;1053:151-2
138. Eller M, Williams DR. alpha-Synuclein in Parkinson disease and other neurodegenerative disorders. Clin Chem Lab Med 2011;49:403-8
139. Chen J, Tang XQ, Zhi JL, et al. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 2006;11:943-53 (Pubitemid 43876825)
140. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006;97:105-15
141. Pandey N, Strider J, Nolan WC, et al. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol 2008;115:479-89
142. Wang J, Du XX, Jiang H, et al. Curcumin attenuates 6-hydroxydopamine- induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol 2009;78:178-83
143. Ortiz-Ortiz MA, Moran JM, Ruiz-Mesa LM, et al. Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci Lett 2010;468:120-4
144. Wang MS, Boddapati S, Emadi S, et al. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci 2010;11:57
145. Yu S, Zheng W, Xin N, et al. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res 2010;13:55-64
146. Jaisin Y, Thampithak A, Meesarapee B, et al. Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci Lett 2011;489:192-6
147. Liu Z, Yu Y, Li X, et al. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol Res 2011;63:439-44
148. Vajragupta O, Boonchoong P, Watanabe H, et al. Manganese complexes of curcumin and its derivatives: evaluation for the radical scavenging ability and neuroprotective activity. Free Radic Biol Med 2003;35:1632-44 (Pubitemid 37532914)
149. Zbarsky V, Datla KP, Parkar S, et al. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 2005;39:1119-25 (Pubitemid 41358566)
150. Rajeswari A. Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Eur Rev Med Pharmacol Sci 2006;10:157-61 (Pubitemid 44468939)
151. Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 2008;16:96-9 (Pubitemid 351521747)
152. Mythri RB, Veena J, Harish G, et al. Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease. Br J Nutr 2011;106:63-72
153. Mansouri Z, Sabetkasaei M, Moradi F, et al. Curcumin has neuroprotection effect on homocysteine rat model of Parkinson. J Mol Neurosci 2012; In press
154. Tripanichkul W, Jaroensuppaperch EO. Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model. Int J Neurosci 2012; In press
155. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009;14:226-46
156. Perez-Jimenez J, Serrano J, Tabernero M, et al. Bioavailability of phenolic antioxidants associated with dietary fiber: plasma antioxidant capacity after acute and long-term intake in humans. Plant Foods Hum Nutr 2009;64:102-7
157. Belkacemi A, Doggui S, Dao L, et al. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 2011;13:e34 A review highlighting the problems associated with the clinical development of curcumin in the therapy of Alzheimer's disease.
158. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008;28:110-13
159. Thomas-Eapen NE. Turmeric: the intriguing yellow spice with medicine properties. Explore (NY) 2009;5:114-15
160. Shen L, Ji H-F. The pharmacology of curcumin: is it the degradation products? Trends Mol Med 2012;18:138-44
161. Srinivasan M, Sudheer AR, Menon VP. Ferulic acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr 2007;40:92-100 (Pubitemid 46623810)
162. Makni M, Chtourou Y, Fetoui H, et al. Evaluation of the antioxidant, anti-inflammatory and hepatoprotective properties of vanillin in carbon tetrachloride-treated rats. Eur J Pharmacol 2011;668:133-9
163. Yan JJ, Cho JY, Kim HS, et al. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001;133:89-96
164. Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun 2005;336:444-9 (Pubitemid 41267250)
165. Thomas P, Wang YJ, Zhong JH, et al. Grape seed polyphenols and curcumin reduce genomic instability events reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat Res 2009;661:25-34